Napredna pretraga

Pregled bibliografske jedinice broj: 770201

The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum- based therapy: a meta-analysis


Bišof, Vesna; Zajc Petranović, Matea; Rakušić, Zoran; Samardžić, Kristina Ruža; Juretić, Antonio
The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum- based therapy: a meta-analysis // European archives of oto-rhino-laryngology, 273 (2016), 9; 2305-2317 doi:10.1007/s00405-015-3710-x (međunarodna recenzija, pregledni rad, znanstveni)


Naslov
The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum- based therapy: a meta-analysis

Autori
Bišof, Vesna ; Zajc Petranović, Matea ; Rakušić, Zoran ; Samardžić, Kristina Ruža ; Juretić, Antonio

Izvornik
European archives of oto-rhino-laryngology (0937-4477) 273 (2016), 9; 2305-2317

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, znanstveni

Ključne riječi
ERCC1 ; Platinum-based chemotherapy ; HNSCC ; Chemoradiotherapy ; Meta-analysis

Sažetak
Excision repair cross-complementation group 1 (ERCC1) protein has been extensively investigated as a prognostic and predictive factor for platinum-based treatment in head and neck squamous cell carcinoma (HNSCC) but with inconsistent results. We performed the present meta-analysis to better elucidate this issue in advanced HNSCC. A literature search was conducted using the PubMed and Web of Science databases. The inclusion criteria were head and neck cancer patients with platinum-based treatment and evaluation of the correlation between ERCC1 expression and clinical outcomes [objective response rate (ORR), progression- free survival (PFS), and overall survival (OS), both unadjusted and adjusted estimates]. In high vs. low pooled analyses, high ERCC1 expression was associated with unfavorable OS [hazard ratio (HR)=1.95, 95% confidence interval (CI) 1.18–3.21, p=0.009], PFS (HR = 2.39, 95% CI 1.74–3.28, p=0.000) and ORR (odds ratio=0.48, 95% CI 0.23–0.98, p=0.044). In the subgroup analysis of adjusted OS estimates, ERCC1 was a predictor of shorter survival in Asians (HR=3.13, 95% CI 2.09–4.70, p=0.000) and Caucasians (HR=2.02, 95% CI 1.32–3.07, p=0.001) but of longer survival in South Americans (HR=0.17, 95% CI 0.07–0.40, p=0.000). Immunohistochemistry proved to be of predictive value irrespective of used antibody (p=0.009). In the stratified analysis according to the tumor site, ERCC1 expression was associated with OS in nasopharyngeal cancer (HR=2.72, 95% CI 1.79–4.13, p=0.000). ERCC1 has a potential to become predictive and prognostic factor enabling treatment tailoring in HNSCC patients.

Izvorni jezik
Engleski

Znanstvena područja
Biologija, Kliničke medicinske znanosti



POVEZANOST RADA


Ustanove
Medicinski fakultet, Zagreb,
Institut za antropologiju,
Klinički bolnički centar Zagreb,
Medicinski fakultet, Osijek

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Uključenost u ostale bibliografske baze podataka:


  • Academic OneFile
  • CNKI
  • Current Abstracts
  • EBSCO
  • Google Scholar
  • Global Health
  • Health Reference Center Academic
  • Index to Scienctific & Technical Proceedings
  • Journal Citation Reports/Science Edition
  • OCLC
  • Pathway Studio
  • Reaxys
  • Summon by ProQuest


Citati